Electrolyte deficiency after the novel coronavirus infection and post-COVID asthenia
DOI: 10.32364/2587-6821-2021-5-5-245-251
E.Yu. Ebzeeva1, O.D. Ostroumova1, I.F. Krotkova1, E.V. Mironova2, R.R. Romanovskiy1
1Russian Medical Academy of Continuous Professional Education, Moscow,
Russian Federation
2Central Clinical Hospital "RZD-Meditsina", Moscow, Russian Federation
Asthenia is a non-specific syndrome common in general practice and occurs in patients with acute and chronic somatic disorders, including infectious ones. The novel coronavirus infection (COVID-19) is one of the leading causes of severe and persistent asthenia. The hypothalamic-pituitary-adrenal axis is essential for the development of asthenia since its dysfunction provoked by various factors (including infections) results in electrolyte metabolism impairment with hypokalemia and hypomagnesemia. This paper describes a hypothetical pathogenic mechanism of asthenia after the COVID-19, which implies over-activation of the renin-angiotensin-aldosterone system that, in particular, leads to hypokalemia. The role of pharmacotherapy prescribed for the COVID-19 is highlighted. Study results demonstrate a high rate of hypokalemia in patients with the COVID-19 and suggest a direct correlation between the severity of hypokalemia and the activity of viral infection. Furthermore, the detec tion of electrolyte abnormalities is essential in both acute infection and convalescence. Finally, the authors consider ways of relieving this pathological condition.
Keywords: novel coronavirus infection, COVID-19, post-infectious asthenia, angiotensin-converting enzyme, hypokalemia, hypomagnesemia.
For citation: Ebzeeva E.Yu., Ostroumova O.D., Krotkova I.F. et al. Electrolyte deficiency after the novel coronavirus infection and post-COVID asthenia. Russian Medical Inquiry. 2021;5(5):245–251 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-245-251.
Acknowledgment
The authors and Editorial Board are grateful to Gedeon Richter LLC for providing full-text foreign articles required to write the review.
About the authors:
Elizaveta Yu. Ebzeeva — C. Sc. (Med.), associate professor of the Department of Therapy and Polymorbid Diseases, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0001-6573-4169.
Olga D. Ostroumova — Dr. Sc. (Med.), Professor, Head of the Department of Therapy and Polymorbid Diseases, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0002- 0795-8225.
Irina F. Krotkova — C. Sc. (Med.), associate professor of the Department of Therapy and Polymorbid Diseases, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0002-9597-1648.
Elena V. Mironova — C. Sc. (Med.), Head of Cardiology Department, Central Clinical Hospital "RZD-Meditsina"; 84, Volokolamskoe road, Moscow, 125367, Russian Federation; ORCID iD 0000-0002-2988-1767.
Rostislav R. Romanovskiy — postgraduate student of the Department of Therapy and Polymorbid Diseases, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0001-5553-856X.
Contact information: Elizaveta Yu. Ebzeeva, е-mail: veta-veta67@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 29.06.2021.
Revised 22.07.2021.
Accepted 16.08.2021.
2. Dyukova G.M. Asthenic syndrome: problems of diagnosis and therapy. Effektivnaya nevrologiya i psikhiatriya. 2012;1:16–22 (in Russ.).
3. Nemkova S.A. Modern principles of treatment of post-infectious asthenic conditions in children. RMJ. 2016;6:368–372 (in Russ.).
4. Ostroumova T.M., Ostroumova О.D., Ebzeeva E.Yu., Arablinskiy N.A. Fatigue and cognitive impairment in post-COVID-19 patients. Actovegin potential in their management. Сlinical Review for General Practice. 2021;1:28–34 (in Russ.). DOI: 10.47407/kr2021.2.1.00035.
5. ICD-10 — International classification of diseases of the 10th revision. Version 2019 (Electronic resource.) URL: https://mkb-10.com. (access date:06.11.2021) (in Russ.).
6. Oronsky B., Larson C., Hammond T.C. et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2021 Feb 20:1–9 (Online ahead of print.). DOI: 10.1007/s12016-021-08848-3.
7. Lukianchikov V.S. Hypokalemia. RMJ. 2019;1(I):28–32 (in Russ.).
8. Silhol F., Sarlon G., Deharo J.C., Vaïsse B. Downregulation of ACE 2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertens Res. 2020;43(8):854–856. DOI: 10.1038/s41440-020-0476-3.
9. Lippi G., South A.M., Henry B.M. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem. 2020;57(3):262–265. DOI: 10.1177/0004563220922255.
10. Büyükcam F., Calik M., Erkuran M.K., Akay H. Hypokalemia and muscle paralysis after low-dose methylprednisolone. Am J Emerg Med. 2011;29(5):573.e1–573.e2. DOI: 10.1016/j.ajem.2010.05.008.
11. Singh Rehan H., Hotha P. Antimicrobial Agents-induced Hypokalemia: A Possible Causality Association. Indian J Crit Care Med. 2019;23(4):175–177. DOI: 10.5005/jpjournals-10071-23148.
12. Ostroumova O.D., Pereversev A.P., Klepikova M.V. Drug-induced electrolyte imbalance. Part 1. Drug-induced hypokalemia. RMJ. 2020;11:20–29 (in Russ.).
13. Haddy F.J., Vanhoutte P.M., Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R546–52. DOI: 10.1152/ajpregu.00491.2005.
14. Hibino H., Inanobe A., Furutani K. et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90(1):291–366. DOI: 10.1152/physrev.00021.2009.
15. Filippini T., Violi F., D’Amico R., Vinceti M. The effect of potassium supplementation on blood pressure in hypertensive subjects: A systematic review and meta-analysis. Int J Cardiol. 2017;230:127–135. DOI: 10.1016/j.ijcard.2016.12.048.
16. Ascherio A., Rimm E.B., Hernán M.A. et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation. 1998;98(12):1198–204. DOI: 10.1161/01.CIR.98.12.1198.
17. Ekmekcioglu C., Elmadfa I., Meyer A.L., Moeslinger T. The role of dietarypotassium in hypertension and diabetes. J Physiol Biochem. 2016;72(1):93–106. DOI: 10.1007/s13105-015-0449-1.
18. Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I., Blokhina O.E. Potassium and magnesium deficiency, its role in cardiovascular disease development and possibilities of correction. Consilium Medicum. 2019;21(1):67–73 (in Russ.). DOI: 10.26442/20751753.2019.1.190240.
19. Whang R., Whang D.D., Ryan M.P. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med. 1992;152(1):40–45.
20. Opie L.H. Medicines in the practice of a cardiologist. Translation from English. M.; 2010 (in Russ.).
21. Katopodis P., Karteris E., Katopodis K.P. Pathophysiology of drug-induced hypomagnesaemia. Drug Saf. 2020;43(9):867–880. DOI: 10.1007/s40264-020-00947-y.
22. Jee S.H., Miller E.R., Guallar E. et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens. 2002;15(8):691–691. PMID: 12160191.
23. Bo S., Pisu E. Role of dietary magnesium in cardiovascular disease prevention,insulin sensitivity and diabetes. Curr Opin Lipidol. 2008;19(1):50–56. DOI: 10.1097/MOL.0b013e3282f33ccc.
24. Uzui H., Lee J.-D. Role of magnesium in hypertension therapy. Clinical Calcium. 2005;15(11):117–122. DOI: CliCa051118791884.
25. Preuss H.G. Diet, genetics and hypertension. J Am Coll Nutr. 1997;16(4):296–305. DOI: 10.1080/07315724.1997.10718690.
26. Reffelmann T., Ittermann T., Dörr M. et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011;219(1):280–284. DOI: 10.1016/j.atherosclerosis.2011.05.038.
27. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID 19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.
28. Cummings M.J., Baldwin M.R., Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. DOI: 10.1016/S0140-6736(20)31189-2.
29. Jensen H.K., Brabrand M., Vinholt P.J. et al. Hypokalemia in acute medical patients: risk factors and prognosis. Am J Med. 2015;128(1):60–67.e1. DOI: 10.1016/j.amjmed.2014.07.022.
30. Chen D., Li X., Song Q. et al. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). MedRxiv. 2020. DOI: 10.1101/2020.02.27.20028530.
31. Tsiberkin A.I., Klyaus N.A., Sazonova Yu.V., Semenov A.P. Hypokalemia in hospitalized patients with pneumonia associated with COVID-19. Arterial Hypertension. 2020;26(4):462–467 (in Russ.) DOI: 10.18705/1607-419X-2020-26-4-462-467.
32. Moreno P.O., Leon-Ramirez J.M., Fuertes-Kenneally L. et al. COVID19-ALC Research Group. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. Int J Infect Dis. 2020;100:449–454. DOI: 10.1016/j.ijid.2020.09.033.
33. Collins A.J., Pitt B., Reaven N. et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–221. DOI: 10.1159/000479802.
34. Krijthe B.P., Heeringa J., Kors J.A. et al. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013;168(6):5411–5415. DOI: 10.1016/j.ijcard.2013.08.048.
35. Yang Y., Ma Y., Zhang J. et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
36. Shlyakho E.V., Konradi A.O., Villevalde S.V. et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801 (in Russ.). DOI: 10.15829/1560-4071-2020-3-3801.
37. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. DOI: 10.1001/jama.2020.1585.
38. Chow C., Symonds C., Zochodne D. Hyperglicemia, lumbar plexopathy and hypocalemic rhabdomiolisis complicating Conn’s syndrome. Can J Neurol Sci. 1997;(1):67–69.
39. Gardner D., Shobek D. Basic and clinical endocrinology. Book 2. Translation from English M.: Binom; 2011 (in Russ.).
40. Molashenko N.V., Platonova N.M., Yukina M.Yu. et al. Primary aldosteronism. Collection of guidelines. Tver: Triad; 2017 (in Russ.).
41. Kosmacheva E.D., Chikhladze N.M., Atamanhakova D.M. et al. Heart rhythm disturbances in patients with arterial hypertension with primary aldosteronism. Kardiologiia. 1990;3:97–98 (in Russ.).
42. Laurie L., Jacobs G., Gourna Paleoudis E. et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020;15(12):e0243882. DOI: 10.1371/journal.pone.0243882.
43. Personality Psychology Tests. Test questionnaire for the diagnosis of asthenia. Asthenic State Scale (SHAS) L.D. Malkova (Electronic resource.) URL: https://psycabi.net/testy/129-test-dlya-diagnostiki-astenii-shkala-astenicheskogo-sostoyaniya-shas-l-d-malkovoj (access date: 06.11.2021) (in Russ.).
44. Yancey J.R., Thomas S.M. Chronic fatigue syndrome: diagnosis and treatment. Am Fam Physician. 2012;86(8):741–746.
45. Komarov S.G. Chronic fatigue syndrome is a disease of civilization. Algorithms for diagnostics and medical care. In: Proceedings of the VIII International Congress "Health and Education in the XXI Century; the concept of civilization diseases". M.: Publishing house of RUDN University; 2007: 320–322 (in Russ.).
46. Bulanova E.L., Bulanov A.Yu., Krasnoselsky M.Yu. Potassium-magnesium asparaginate — infusion solution with antiarrhythmic properties Trudnyj Patient. 2012;10:2–7 (in Russ.).
47. Averin E.E., Nikitin A.E., Pozdnyak A.O. et al. Expert Council Resolution. Practical Aspects of the Diagnosis and Correction of Potassium and Magnesium Deficiency States. Kardiologiia. 2020;60(2):155–164. (in Russ.). DOI: 10.18087/cardio.2020.2.n972.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
